How to access Tavalisse from the UAE — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A UAE patient with chronic immune thrombocytopenia (ITP) that has had insufficient response to prior treatment may receive a prescription for Tavalisse (fostamatinib) from their treating haematologist. Tavalisse is FDA-approved in the United States and developed by Rigel Pharmaceuticals (partnered with Grifols in select EU markets). It is a first-in-class oral spleen tyrosine kinase (SYK) inhibitor — a non-TPO mechanism for chronic ITP. Where Tavalisse is not on a UAE hospital formulary, a named-patient import pathway via MoHAP is the legitimate route.

This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.

The clinical situation

Tavalisse is an oral tablet taken twice daily, starting at 100 mg BID and titrating up to 150 mg BID if platelet response is inadequate. Because SYK inhibition affects Fcγ-receptor-mediated platelet destruction, the mechanism is distinct from thrombopoietin receptor agonists. Key monitoring areas per FDA labeling include blood pressure, hepatic function, neutrophil counts, and diarrhoea management. Your treating haematologist confirms diagnosis, prior therapy history, baseline BP/labs, and the monitoring plan per FDA labeling.

Is Tavalisse legally importable into the UAE?

Yes — through the UAE Ministry of Health and Prevention (MoHAP) named-patient framework, with parallel authority through DoH Abu Dhabi and DHA Dubai depending on the prescribing facility. The pathway allows a UAE-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent registered alternative fits, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.

How the pathway works, step by step

1. Consultation with your treating haematologist. Diagnosis, platelet history, prior therapy history (steroids, IVIG, TPO agonists, rituximab, splenectomy), and clinical rationale for SYK inhibition.
2. Pre-treatment workup. Baseline BP, CBC, LFTs per labeling.
3. MoHAP named-patient application. The physician or hospital pharmacy files the application.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner.
5. Shipment. Tavalisse is an oral tablet with standard storage; shipment includes tamper-evident packaging and chain-of-custody documentation.
6. Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription.

What documentation your physician needs

Your physician will typically need to provide:

• Clinical rationale letter confirming chronic ITP, prior therapies and responses, and Tavalisse as the indicated treatment
• Verification of their UAE medical licence
• Patient identifier
• Baseline BP and labs confirmation
• Planned dose titration and monitoring cadence

Reserve Meds provides a physician documentation kit that bundles the templates MoHAP reviewers expect to see for oral targeted-kinase therapies used in haematology.

Costs and timing

Tavalisse's US cash-pay reference price for a 30-day supply at maintenance dosing sits in a broad indicative range of roughly USD 12,000–16,000. International logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.

Indicative timing — not guaranteed — for first dose after cohort intake opens is approximately 10–21 days from the moment a complete application is submitted. Refills ship on a rolling basis.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Tavalisse specifically, we provide:

• Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and for MoHAP review.
• Logistics. Tamper-evident, internationally tracked shipment.
• Concierge case lead. A named point of contact.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.

Frequently asked

Is this legal in the UAE? Yes, when executed through the MoHAP named-patient framework with appropriate documentation.

How is Tavalisse different from TPO receptor agonists? TPO agonists stimulate platelet production; Tavalisse reduces antibody-mediated platelet destruction through SYK inhibition. In patients who have had insufficient response to TPO agonists, the alternative mechanism is why Tavalisse may be considered.

What monitoring is important? Blood pressure, LFTs, CBC, and diarrhoea management are labeled monitoring areas. Your haematologist will schedule these checks.

Will private insurance cover this? Cash-pay is the default. Some UAE insurers reimburse named-patient imports case by case; we supply documentation for your submission but do not process insurance claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Tavalisse coordination in the UAE.

> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.